The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas

Current Eye Research

Volumn 34, Issue 2, 2009, Pages 85-91

  Oh, Joo Youn ^a,b   Kim, Mee Kum ^a,b   Shin, Mi Sun ^b   Lee, Hyun Ju ^b   Lee, Jin Hak ^a,b   Wee, Won Ryang ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Angiogenesis; Bevacizumab; Cornea; Epithelium; Inflammation

Indexed keywords

BEVACIZUMAB; GAMMA INTERFERON; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CORNEA; CORNEA BURN; CORNEA LIMBUS; CORNEA NEOVASCULARIZATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIZATION; IMMUNOFLUORESCENCE; KERATITIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPRAGUE DAWLEY RAT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BURNS, CHEMICAL; CONJUNCTIVA; CORNEA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; ETHANOL; EYE BURNS; INJECTIONS; MALE; RATS; SOLVENTS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 60749092838     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680802607740     Document Type: Article

References (22)

1. Azar DT. Corneal angiogenic privilege: Angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2006;104:264-302.
2. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006;113:e1-12.
3. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008;115:e33-38.
4. Uy HS, Chan PS, Ang RE. Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome. Cornea 2008;27:70-73.
5. Carrasco MA. Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea 2008;27:743-735.
6. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 2008;33:22-28.
7. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 2008;27:142-147.
8. Coma MC, Sobrin L, Onal S, et al. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 2007;114:1574-1579.
9. Kurup S, Lew J, Byrnes G, et al. Therapeutic efficacy of intravitreal bevacizumab on posterior uveitis complicated by neovascularization. Acta Ophthalmol 2008; Epub ahead of print.
10. Bock F, Onderka J, Dietrich T. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007;48:2545-2552.
11. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-4085.
12. Scott IU, Edwards AR, Beck RW, et al. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-1867.
13. Kriechbaum K, Michels S, Prager F. IntravitrealAvastin formacular oedema secondary to retinal vein occlusion: A prospective study. Br J Ophthalmol 2008;92:518-522.
14. Papathanassiou M, Theodossiadis PG, Liarakos VS, et al. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animalmodel. Am J Ophthalmol 2008;145:424-431.
15. Hosseini H, Nejabat M, Mehryar M, et al. Bevacizumab inhibits corneal neovascularization in an alkali burn-induced model of corneal angiogenesis. Clin Exp Ophthalmol 2007;35:745-748.
16. Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 2007;91:804-807.
17. Barros LF, Belfort R Jr. The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. An Acad Bras Cienc 2007;79:389-394.
18. Hurmeric V, Mumcuoglu T, Erdurman C, et al. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea 2008;27:357-362.
19. Yoeruek E, Ziemssen F, Henke-Fahle S, et al. Tübingen Bevacizumab Study Group. Safety, penetration, and efficacy of topically applied bevacizumab: Evaluation of eye drops in corneal neovascularization after chemical burn. Acta Ophthalmol 2008;86:322-328.
20. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004;113:1040-1050.
21. Cursiefen C, Maruyama K, Jackson DG, et al. Time course of angiogenesis and lymphangiogenesis after brief corneal inflammation. Cornea 2006;25:443-447.
22. Oh JY, Kim MK, Shin MS, et al. The anti-inflammatory and antiangiogenic role of mesenchymal stem cells in corneal wound healing following chemical injury. Stem Cells 2008;26:1047-1055.